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Purpose. Vernal keratoconjunctivitis (VKC) is a chronic allergic disease mainly affecting boys in prepubertal age and usually
recovering after puberty. To evaluate a possible role of sex hormones in VKC, serum levels of sex hormones in children and
adolescents with VKC were assessed.Methods. 12 prepubertal and 7 early pubertal boys with active VKC and 6 male patients with
VKC in remission phase at late pubertal age and 48 healthy age and sex-matched subjects were included. Serum concentration of
estrone, 17 beta-estradiol, dehydroepiandrosterone-sulfate, total testosterone and free testosterone, dihydrotestosterone (DHT),
cortisol, delta-4-androstenedione, follicle-stimulating hormone, luteinizing hormone, and sex-hormones binding globuline
(SHBG) were evaluated. Results. Serum levels of Estrone were significantly increased in all groups of patients with VKC when
compared to healthy controls (𝑃 < 0.001). Prepubertal and early pubertal VKC showed a significant decrease in DHT (𝑃 = 0.007
and 𝑃 = 0.028, resp.) and SHBG (𝑃 = 0.01 and 𝑃 = 0.002, resp.) when compared to controls and serum levels of SHBG were
increased in late pubertal VKC in remission phase (𝑃 = 0.007). Conclusions and Relevance.VKC patients have different circulating
sex hormone levels in different phases of the disease and when compared to nonallergic subjects. These findings suggest a role
played by sex hormones in the pathogenesis and/or activity of VKC.
1. Introduction
Vernal keratoconjunctivitis (VKC) is an ocular allergic dis-
ease mainly affecting the paediatric population, as it usually
recovers spontaneously after puberty [1]. Similarly to other
atopic conditions, VKC has a different prevalence between
males and females. In particular, boys are two to four times
more likely to develop VKC [1–4]. We previously described
a significant increase of conjunctival estrogen and proges-
terone receptors in childrenwithVKCas compared to healthy
subjects. These findings, together with the higher disease
prevalence in boys, suggest an influence of sex hormones on
VKC development and/or activity [5].
In line with this, increasing evidence demonstrates a
close relationship between sex hormones and ocular surface
conditions such as dry eye, autoimmune diseases, contact
lens intolerance, corneal angiogenesis, and wound healing
[6].
Changes in sex hormonemetabolism and balance may be
a predisposing factor to immune-mediated diseases, includ-
ing allergy [7, 8]. It is generally accepted that estrogens
exert immunoenhancing activities, at least on the humoral
immune response, while androgens exert immunosuppres-
sive effects on both humoral and cellular immune responses
and seem to represent natural anti-inflammatory hormones
[8]. Particularly, androgens such as dehydroepiandrosterone
Hindawi Publishing Corporation
Journal of Immunology Research
Volume 2015, Article ID 945317, 6 pages
http://dx.doi.org/10.1155/2015/945317
2 Journal of Immunology Research
(DHEA), dehydroepiandrosterone-sulfate (DHEA-S), and
testosterone may influence the balance between type-1 and
type-2 helper T cells (Th1/Th2), immunoglobulin (Ig) E
synthesis, and eosinophil proliferation, thus modulating the
development of allergic reactions [9–11]. On the other hand,
estrogens may stimulate the allergic response by inducing
synthesis of antibodies and by stimulating mast cell degran-
ulation through estrogen receptor-alpha [8, 12]. Changes in
circulating sex hormone levels and sex hormone-binding
globulin (SHBG) have been described in patients with atopic
dermatitis, asthma, hereditary angioneurotic oedema, and
chronic urticaria [10, 13, 14]. However, circulating levels
of sex hormones in patients with VKC have not yet been
evaluated.
In the present study, serum concentration of estrone
(E1), 17 beta-estradiol (E2), DHEA-S, total testosterone
(TT), free testosterone (FT), dihydrotestosterone (DHT),
cortisol, delta-4-androstenedione (D4A), follicle-stimulating
hormone (FSH), luteinizing hormone (LH), and SHBG
were evaluated in male patients with VKC in active- and
remission-phase and were compared to healthy age and sex-
matched subjects.
2. Methods
Nineteen consecutive male patients with active VKC (Bonini
grade ≥ 1) were included in this study [15]. The patients were
divided in 12 prepubertal boys (age range 6 to 9 years, LH
< 1 IU/L, and TT < 30 ng/100mL) and 7 early pubertal boys
(𝑁 = 7, age range 10 to 12 years, LH < 3 IU/L, and TT <
200 ng/100mL). Six additional late pubertal (14 to 17 years of
age, LH 1 to 10 IU/L and TT > 200 ng/100mL) patients with
VKC in remission phase (Bonini grade < 1) were included
(Table 1).
Twenty healthy nonallergic prepubertal males along with
16 early pubertal and 12 late pubertal males were used as
controls. Written informed consent for participation was
obtained from their parents according to the local require-
ments. The study was performed in accordance with the
tenants of the Declaration of Helsinki following approval of
the local IRB.
Girls with VKC were not included in this study to avoid
the confounding factor of sex hormones blood levels differ-
ences due to gender. Patients with ocular and/or systemic
associated diseases were excluded with the exception of
associated atopic diseases. None of the patients or healthy
subjects were taking or previously took systemic steroids,
phenytoin, or other medications known to interfere with sex
hormone metabolism.
Vernal Keratoconjunctivitis diagnosis was based on a
history of ocular surface inflammation characterised by
itching, photophobia, tearing and mucous discharge, the
presence of a giant papillary reaction on the upper tarsal con-
junctiva, and/or at the limbus associated with the presence of
eosinophils in conjunctival scrapings.
The following clinical and demographic data of VKC
patients were collected: age, duration of disease, history
of associated atopic diseases, and positive reaction to skin
PRICK tests.
Disease activity was graded according to the Bonini VKC
severity score, as follows: grade 0 (quiescent) = absence of
ocular symptoms; grade 1 (mild) = presence of ocular symp-
toms but not photophobia; grade 2 (moderate) = presence
of symptoms and photophobia; grade 3 (moderate) = pres-
ence of ocular symptoms and mild-to-moderate superficial
punctuate keratitis (SPK); grade 4 (very severe) = presence
of diffuse SPK and/or corneal ulcer [15]. Patients with past
history of VKC, absent or mild-intermittent ocular symp-
toms, and the presence of conjunctival papillary reaction
associated with subconjunctival fibrosis were considered in
the remission phase of the disease [16].
Blood samples were obtained in the morning from all
subjects. Sex hormone serum concentrationswere performed
following the standard hospital procedures by the Clinical
Laboratory of the University of Tor Vergata. In particular,
estrone (E1), 17-beta estradiol (E2), DHEA-S, TT, FT, DHT,
FSH, and LH, and delta-4-androstenedione were determined
by radio-immunoassay (RIA) and serum concentration of
SHBGwas performed by immunoradiometric assay (IRMA).
The total serum IgE concentration (PRIST) was also assessed
by radio-immunoassay (RIA).
The serum concentrations of sex hormones in patients
with VKC were compared to those of age-matched controls
by independent samples 𝑡-test. Clinical grade, demographic
characteristics, and IgE concentration were related with sex
hormone levels by Spearman rho test and independent
samples 𝑡-test (SPSS for Windows, V.15, SPSS, Inc., Chicago,
IL, USA). 𝑃 values below 0.05 were considered statistically
significant.
3. Results
Twenty-five consecutive male VKC patients were included
in this study. Clinical characteristics of patients with VKC
included in the study are listed in Table 1.
Patients with VKC in active phase (𝑁 = 19) showed de-
creased serum levels of DHT, SHBG, and FSH (𝑃 < 0.001,
𝑃 < 0.001, and 𝑃 < 0.001, resp.) and increased levels
of estrone and FT (𝑃 < 0.001, 𝑃 = 0.007, resp.) when
compared to age-matched healthy subjects (Table 2). These
changes were confirmed when patients with VKC were
divided in prepubertal (𝑁 = 12) and early pubertal (𝑁 =
7) groups. Particularly, serumDHT and SHBG concentration
were decreased and serum estrone was increased in both the
prepubertal (𝑃 = 0.007, 𝑃 = 0.01, and 𝑃 < 0.001, resp.)
and early pubertal VKC groups (𝑃 = 0.028, 𝑃 = 0.002, and
𝑃 = 0.001, resp.) when compared to age-matched healthy
subjects. Early pubertal VKC patients also showed increased
serum concentrations of FT (𝑃 = 0.002) and early pubertal
patients showed decreased FSH serum levels (𝑃 = 0.002)
when compared to healthy subjects.
Patient with VKC in the remission phase showed in-
creased serum concentration of SHBG and estrone (𝑃 =
0.007 and 𝑃 = 0.007, resp.) and no significant difference
in DHT concentration when compared to healthy subjects.
In addition, a significant decrease of FT and DHEA-S (𝑃 =
0.033, 𝑃 = 0.012, resp.) levels were observed when compared
to healthy controls (Table 3).
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Table 1: Clinical characteristics of patients included in this study.
Total Prepuberty Early puberty Late puberty
Patients𝑁 25 12 7 6
Atopic associated diseases (𝑁)
Rhinitis 2 0 2 0
Asthma 5 2 1 2
Atopic dermatitis 2 2 0 0
Atopic dermatitis and asthma 4 1 1 2
None 12 7 3 2
Skin prick test (𝑁)
Positive 14 7 3 4
Negative 11 5 4 2
Total IgE (U/mL) 215 ± 257 323 ± 347 261 ± 189 111 ± 76
Duration of VKC (years)
Mean ± SD 5.6 ± 3.4 3 ± 1.4 6.1 ± 2.2 10 ± 2.6
VKC type (𝑁)
Tarsal 22 11 7 4
Limbal 3 1 0 2
Mixed 0 0 0 0
VKC course
Seasonal 14 6 5 3
Perennial 11 6 2 3
VKC grade
0—quiescent 6 0 0 6
1—mild 2 2 0 0
2—moderate 9 6 3 0
3—severe 4 1 3 0
4—very severe 4 3 1 0
SD: standard deviation; VKC: vernal keratoconjunctivitis.
Patients with positive reaction to skin prick test showed
a significantly higher estrone serum concentration when
compared to patients with no skin reaction, regardless of
age and stage of VKC activity. In particular, estrone serum
concentration in patients with active VKCwas 40±14 pg/mL
in patients with positive skin test, as compared to 23 ±
12 pg/mL inVKCwith negative skin test (𝑃 = 0.044). Patients
with VKC in remission phase also showed higher estrone
levels in the groupwith positive skin prick test as compared to
negative skin prick test (43±3 pg/mL versus 31±6 pg/mL,𝑃 =
0.049). No significant correlations were observed between
serum IgE levels, clinical grade of VKC, and sex hormones
levels.
4. Discussion
In this study we demonstrated that boys with active VKC
have different circulating sex hormone levels as compared
to healthy subjects. VKC is a chronic allergic disease, and
as in other atopic conditions such as atopic eczema and
asthma, boys are more frequently affected compared to girls,
with this ratio becoming almost equal after puberty due to
a spontaneous remission in the late puberty. It has been
hypothesized that the recovery of VKC at puberty may be the
result of a protective function of androgens [1, 2, 17, 18]. Both
androgens and estrogens exert a role in immune diseases.
Although the precise mechanisms by which these steroid
hormones affect the immune system are not completely
elucidated, their effects may be responsible for the gender
differences in the onset and course of immune diseases,
including allergic conditions [8, 17, 19, 20].
Our data show that children with VKC have differences
in circulating sex hormone levels when compared to age and
sex-matched healthy subjects that are potentially responsible
for disease activity. In line with our hypothesis of a role
played by sex hormones in the pathogenesis and remission
of VKC, in this study we also observed that late pubertal
(adolescent) VKC patients with disease in remission phase
did not show the same differences in sex hormones’ pattern
when compared to healthy controls. Particularly, pre- and
early pubertal boys with active VKC showed a decrease in
DHT and SHBG associated with an increase in Estrone
serum concentrations, while late pubertal boys with VKC in
remission showed a normalization of DHT and an increase in
estrone and SHBG serum levels.
All patients with active VKC—regardless of age—showed
a consistent significant reduction of DHT, the more active
androgen. DHT is synthesized from testosterone in periph-
eral tissues by the 5𝛼-reductase enzyme [21]. DHT is able
to depress the systemic immune response, and it has been
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Table 2: Sex hormones serum levels in active VKC and healthy subjects.
Total Prepubertal Early pubertal
VKC Healthy VKC Healthy VKC Healthy
𝑁 19 36 12 20 7 16
Age
Mean ± SD 8.7 ± 2 8.5 ± 2.9 7.3 ± 0.9 7 ± 1.3 11 ± 0.7 11 ± 1.1
Range 6–12 6–13 6–9 6–9 9–12 9–13
LH (mUI/mL)
Mean ± SD 0.5 ± 0.3 0.6 ± 0.5 0.4 ± 0.2 0.4 ± 0.2 0.9 ± 0.5 0.8 ± 0.5
Range 0.2–1.2 0.1–2 0.2–0.7 0.1–0.8 0.5–1.2 0.1–2
FSH (mUI/mL)
Mean ± SD 0.7 ± 0.5∗ 1.4 ± 0.7 0.6 ± 0.4 1 ± 0.6 0.8 ± 0.6∗ 1.8 ± 0.8
Range 0.3–1.7 0.2–4 0.3–1.2 0.2–3 0.3–1.7 0.6–4
Total testosterone (ng/100mL)
Mean ± SD 28.7 ± 47 18 ± 12 13 ± 9.1 9.8 ± 4.2 36 ± 24 26 ± 12
Range 1–73 4–48 1–27 4–17 7–73 6–48
Free testosterone (ng/100mL)
Mean ± SD 2.7 ± 4.7∗ 1 ± 1 2 ± 2.8∗ 0.4 ± 0.1 4.1 ± 7.4 1.6 ± 1
Range 0.5–19.2 0.2–4.9 0.5–8.6 0.2–0.5 0.5–19.2 0.2–4.9
DHT (pg/mL)
Mean ± SD 17 ± 11.7 41.7 ± 36.3 15 ± 8.7∗ 21 ± 4 21 ± 19∗ 64 ± 43
Range 3–38 15–140 3–25 15–27 1.3–38 20–140
Estradiol (pg/mL)
Mean ± SD 14.7 ± 6.8 17.7 ± 5.5 14.9 ± 7.2 17.4 ± 4.9 14.2 ± 6.7 17.9 ± 6
Range 5–29 10–34 5–29 10–27 10–24 10–34
Estrone (pg/mL)
Mean ± SD 33.8 ± 18.8∗ 12.8 ± 2.4 33.7 ± 3.5∗ 12 ± 1.7 34.5 ± 3.5∗ 16.5 ± 1.9
Range 10–64 10–18 10–64 10–15 32–37 14–18
DHEAS (ng/mL)
Mean ± SD 855 ± 1008 612 ± 221 707 ± 685 488 ± 186 1111 ± 1440 731 ± 186
Range 87–2640 132–1200 87–2190 132–861 273–2640 358–1200
D4A (ng/mL)
Mean ± SD 0.7 ± 0.7 0.7 ± 0.3 0.7 ± 0.8 0.5 ± 0.2 0.9 ± 0.4 0.9 ± 0.4
Range 0.1–2.5 0.3–2.2 0.1–2.5 0.3–0.9 0.6–1.2 0.6–2.2
Cortisol (ng/mL)
Mean ± SD 122 ± 73 102 ± 49 138 ± 80 107 ± 55 79 ± 28 96 ± 41
Range 31–238 35–205 31–238 35–205 51–107 45–197
SHBG (nmol/L)
Mean ± SD 65.9 ± 41 120 ± 19∗ 76.6 ± 42.6∗ 110.5 ± 28 41.7 ± 25∗ 134 ± 49
Range 21–164 49–208 40–164 84–208 21–78 49–206
VKC: vernal keratoconjunctivitis; ∗𝑃 < 0.05; 𝑁: number; SD: standard deviation; LH: luteinizing hormone; FSH: follicle-stimulating hormone; DHT:
dihydrotestosterone; DHEAS: dehydroepiandrosterone-sulfate; D4A: delta-4-androstenedione; SHBG: sex hormones binding globulin.
demonstrated that DHT plays a major role in suppressing
leukotriene production, a key molecule in the allergic reac-
tion [22]. It has been hypothesized that DHT constitutes
a molecular basis for gender difference in inflammatory
diseases such as asthma. The decrease of serum DHT in
patientswith activeVKCas compared to healthy subjectsmay
be responsible for a lack in the androgen protective function,
which, in turn, could play a role in the age- and gender-related
differences observed in VKC development. However, DHT
levels do not correlate with VKC severity grade, suggesting
that this steroid hormone may predispose to developing
VKC rather than influencing directly the severity of the
inflammatory reaction.The decrease ofDHT inVKCpatients
may result from changes in circulating sex hormones carriers,
such as SHBG, or it may reflect an alteration of sex hormone
pathways. SHBG is a glycoprotein known to bind to circulat-
ing testosterone, DHT, and estradiol, which physiologically
decreases at puberty in association with the increase in
circulating sex hormone levels [23, 24]. In our VKC patients,
the lower levels of DHT do not appear to be related to
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Table 3: Sex hormones serum levels in patients with VKC in





Mean ± SD 14–17 14–17
Range 15.3 ± 1 15.7 ± 1
LH (mUI/mL)
Mean ± SD 2.7 ± 0.6 2.6 ± 1.4
Range 2.1–3.5 1.1–5.4
FSH (mUI/mL)
Mean ± SD 5.8 ± 3.8 5.2 ± 1.5
Range 1.4–8.2 2.9–9.8
Total testosterone (ng/100mL)
Mean ± SD 369 ± 142 369 ± 142
Range 202–593 254–789
Free testosterone (ng/100mL)
Mean ± SD 17.1 ± 42∗ 24.8 ± 6.6
Range 202–593 254–789
DHT (pg/mL)
Mean ± SD 362 ± 37 445 ± 89
Range 320–386 289–593
Estradiol (pg/mL)
Mean ± SD 21 ± 9 27 ± 7
Range 15–37 19–41
Estrone (pg/mL)
Mean ± SD 36.5 ± 7∗ 25.5 ± 2.7
Range 27–43 22–30
DHEAS (ng/mL)
Mean ± SD 1131 ± 700∗ 1783 ± 398
Range 645–2370 1047–2648
D4A (ng/mL)
Mean ± SD 1.4 ± 0.5 1.6 ± 0.3
Range 1–2.2 1.1–2.1
Cortisol (ng/mL)
Mean ± SD 130 ± 63 119 ± 37
Range 56–209 76–203
SHBG (nmol/L)
Mean ± SD 73 ± 44∗ 30 ± 9
Range 36–123 13–39
VKC: vernal keratoconjunctivitis; ∗𝑃 < 0.05; 𝑁: number; SD: standard
deviation; LH: luteinizing hormone; FSH: follicle-stimulating hormone;
DHT: dihydrotestosterone; DHEAS: dehydroepiandrosterone-sulfate; D4A:
delta-4-androstenedione; SHBG: sex hormones binding globulin.
changes in serum SHBG concentration. In fact, children with
VKC showed a decrease in SHBG levels when compared to
healthy subjects. These changes in SHBG may explain the
increase of FT levels observed in active VKC. In line with this
hypothesis, late pubertal VKC in remission phase showed a
significant increase of SHBG concentration associated with
lower FT and DHEA-S. The low level of DHEA-S in late
pubertal patients with VKCmay be also caused by a decrease
of adrenal hormones production. Some evidence suggests
that inflammatory conditionsmay be associatedwith reduced
adrenal hormones production and their blood levels when
compared to healthy controls [8, 25, 26]. However, DHEA-
S levels were not changed in patients with VKC in the active
phase when compared to healthy controls.
In line with the overall hypothesis of an involvement
of sex hormones in VKC, circulating estrone levels were
increased in all VKC groups when compared to healthy
subjects. This observation is in line with the well-known
role of estrogens in allergic diseases, including eosinophil
chemotaxis and immune reactions’ triggering [27]. Our
observation that VKC patients with a positive prick skin test
reaction had the highest circulating levels of estrone strongly
supports the role of this hormone in allergic reactions.
Our results on the changes in circulating sex hormone
levels in VKC patients suggest that sex hormone receptors
or pathways at conjunctival inflammatory sites may represent
an additional potential therapeutic target for ocular allergic
diseases.
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